|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00314 SIPAI HEALTH
Nominal 
2.120 0.000 (0.000%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 2,070,984 | -54.638% | 4,565,434 | 4,712,107 | 4,119,478 | 3,473,930 |
| Cost of Sales | (1,759,659) | -57.893% | (4,179,001) | (4,297,409) | (3,782,126) | (3,190,481) |
| Gross Profit | 311,325 | -19.436% | 386,433 | 414,698 | 337,352 | 283,449 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (9,662) | -72.628% | (35,299) | (9,965) | (780,726) | (3,054,835) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (17,926) | -19.596% | (22,295) | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (60) | -67.914% | (187) | (412) | 331 | 137 | |
| Profit / (Loss) before Taxation | (128,156) | -64.464% | (360,641) | (245,666) | (1,368,442) | (3,747,678) | |
| Taxation | 1,378 | -- | (1,191) | (1,041) | (3,322) | (825) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 2,511 | -93.409% | 38,096 | (9,061) | 1,192 | 8,048 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (124,267) | -61.615% | (323,736) | (255,768) | (1,370,572) | (3,740,455) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (6,862) | -46.189% | (12,752) | (27,851) | (13,208) | (6,682) |
| Depreciation & Amortisation | 26,884 | -44.882% | 48,775 | 52,968 | 49,423 | 53,882 |
| Directors' Emoluments | -- | -- | 5,081 | 5,783 | 137,580 | 121,029 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -21.000 | -58.824% | -51.000 | -40.000 | -1,219.000 | -3,761.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.093) | (0.207) | (1.619) | (6.254) |
| NBV per share ($) | 1.249 | -- | 1.604 | 2.126 | 2.407 | -- |
| Remarks: | Real time quote last updated: 01/04/2026 08:27 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -124,267 |
| %Change | -61.615% |
| EPS / (LPS) | RMB -0.210 |
| NBV Per Share (¥) | RMB 1.249 |